Mylan’s receives approval from FDA for biosimilar Herceptin
Mylan is the first pharma company to gain US approval for a biosimilar of Roche’s lucrative cancer antibody, Herceptin. The biosimilar, Ogivri, developed by Mylan and Biocon, was approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin. It brought in almost $7bn in sales last year, with around